Trial intelligence / Profile preview

COMPASS 3: Bosentan-based therapy in PAH

NCT00433329Phase 4Completed

Sponsor
Actelion Pharmaceuticals Ltd
Start
Mar 2007
Primary completion
May 2010
Modality
Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01

Overview

A Phase 4 trial of bosentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Mar 2007; status: completed.

02

Drugs

bosentan
03

Conditions

pulmonary arterial hypertension (PAH)

Beyond the preview

Go deeper on NCT00433329.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00433329.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call